H. pylori

Question 1

In treatment-naive patients w/ H. pylori infection, optimized BQT is recommended as a first-line treatment option

Answer 1

strong, moderate evidence

Question 2

In treatment-naive patients w/ H. pylori infection, rifabutin triple therapy is suggested as a first-line treatment option

Answer 2

conditional, low quality evidence

Question 3

In treatment-naive patients w/ H. pylori infection, dual therapy w/ a PCAB and amoxicillin is suggested as a first-line treatment option

Answer 3

conditional, moderate evidence

Question 4

In treatment-naive patients w/ H. pylori infection and unknown clarithromycin susceptibility, PCAB-clarithromycin triple therapy is suggested over PPI-clarithromycin triple therapy

Answer 4

conditional, moderate evidence

Question 5

In treatment-naive patients w/ H. pylori infection, concomitant therapy is not suggested over bismuth quadruple therapy

Answer 5

conditional, low evidence

Question 6

In treatment-experienced patients w/ persistent H. pylori infection who have not previously received bismuth quadruple therapy, optimized bismuth quadruple therapy is suggested

Answer 6

conditional, very low evidence

Question 7

In treatment-experienced patients w/ persistent H. pylori infection who have previously received PPI-clarithromycin triple therapy, optimized bismuth quadruple therapy is suggested

Answer 7

conditional, low evidence

Question 8

In treatment-experienced patients w/ persistent H. pylori infection who have received bismuth quadruple therapy, rifabutin triple therapy is suggested

Answer 8

conditional, low evidence

Question 9

In treatment-experienced patients w/ persistent H. pylori infection who have not received optimized bismuth quadruple therapy, optimized bismuth quadruple therapy is suggested over quinolone-based therapy

Answer 9

conditional, low evidence